Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026

As the 2026 ASCO Annual Meeting approaches, we’re preparing to see several potentially practice-informing breast cancer presentations spanning hormone receptor (HR)–positive, HER2-positive, triple-negative, and early-stage treatment strategies. Several late-breaking abstracts will explore key questions surrounding treatment sequencing, endocrine resistance, antibody-drug conjugates, and novel HER2-targeted therapies.

We asked readers to share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at this year’s meeting. To read more about these studies and additional abstracts of interest ahead of ASCO 2026, read our in-depth previews on the top triple-negative breast cancer (TNBC) and HR-positive and HER2-positive presentations.

Poll: Which breast cancer abstract are you most excited to see presented at the 2026 ASCO Annual Meeting?

• LBA1000: PFS2 data from ASCENT-04
• LBA1007: PFS2 data from SERENA-6
• LBA1006: persevERA BC
• LBA660: anbenitamab + nab-docetaxel ± carboplatin in HER2+ early breast cancer

Among the most anticipated presentations is the phase 3 persevERA BC trial (NCT04546009), which is evaluating first-line giredestrant plus palbociclib (Ibrance) vs letrozole plus palbociclib in patients with estrogen receptor (ER)–positive, HER2-negative locally advanced or metastatic breast cancer. Although a March 2026 news release indicated that the trial did not meet its primary end point, interest remains high regarding whether a more potent endocrine therapy backbone can improve outcomes when paired with CDK4/6 inhibition.¹ The presentation may also provide insight into whether oral selective ER degraders (SERDs) can benefit patients regardless of ESR1 mutation status, a key question in the evolving HR-positive treatment paradigm.

Additional HR-positive breast cancer data will come from final time to second progression (PFS2) findings from the phase 3 SERENA-6 trial (NCT04964934), which is evaluating first-line camizestrant in patients with advanced breast cancer with emergent ESR1 mutations during treatment with an aromatase inhibitor and a CDK4/6 inhibitor ahead of radiographic disease progression. The study previously generated significant attention after reports that the FDA’s Oncologic Drugs Advisory Committee did not vote in favor of the clinical benefit of this treatment approach for the proposed indication based on available data.² The field is now looking to the PFS2 analysis to better understand whether earlier intervention with camizestrant meaningfully alters long-term disease control and subsequent treatment outcomes.

In triple-negative breast cancer (TNBC), updated findings from the phase 3 ASCENT-04 study (NCT05382286) will examine PFS2 data and outcomes with subsequent therapies among patients with previously untreated PD-L1–positive metastatic TNBC treated with sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) vs chemotherapy plus pembrolizumab. Earlier analyses from the trial demonstrated progression-free survival benefits favoring the sacituzumab govitecan–based combination, helping fuel enthusiasm around moving TROP2-directed antibody-drug conjugates (ADCs) into earlier treatment lines. However, the forthcoming presentation may help answer a critical sequencing question: whether initiating sacituzumab govitecan in the frontline setting provides a durable advantage beyond first progression, or whether reserving the drug for later lines remains a reasonable strategy for some patients.

Another highly anticipated abstract is LBA660, which will present findings from a randomized phase 3 study (KN026-004; NCT06747338) evaluating anbenitamab plus nab-docetaxel with or without carboplatin vs trastuzumab (Herceptin), pertuzumab (Perjeta), and docetaxel with or without carboplatin in patients with HER2-positive early or locally advanced breast cancer. The study is notable for using a comparator regimen that closely reflects standard practice in the United States, potentially increasing the clinical relevance of the findings. Investigators are also eager to learn more about anbenitamab, a biparatopic HER2-targeted antibody designed to bind 2 distinct HER2 epitopes, inhibit signaling activity, and promote HER2 degradation. This mechanism of action may offer an alternative HER2-directed treatment strategy associated with less toxicity compared with ADCs.

On LinkedIn, respondents (n = 8) favored the SERENA-6 PFS2 results (75%), followed by the ASCENT-04 PFS2 data (25%). Results were slightly more varied on X, with respondents (n = 5) favoring the ASCENT-04 PFS2 readout (40%), followed by a tie between the SERENA-6 PFS2 data, the persevERA findings, and the LBA660 presentation (20% each).

Poll: What breast cancer subtype or area are you most excited to learn more about at the 2026 ASCO Annual Meeting?

• HR-positive breast cancer
• HER2-positive breast cancer
• TNBC
• Early-stage breast cancer

On LinkedIn, respondents (n = 68) favored TNBC (49%), followed by HR-positive (24%), HER2-positive (19%), and early-stage (9%) disease. Results were similar on X, with respondents (n = 7) favoring TNBC (57.1%), followed by a tie between HR-positive, HER2-positive, and early-stage disease (14.3% each).

Collectively, these presentations underscore the rapid pace of therapeutic evolution across breast cancer subtypes. From refining endocrine approaches in HR-positive disease to optimizing sequencing strategies in TNBC and exploring novel HER2-targeted platforms in early-stage disease, ASCO 2026 is expected to generate important data that could shape future standards of care.

References

1. Genentech provides update on phase III persevErA study in ER-positive advanced breast cancer. News release. Genentech. March 8, 2026. Accessed May 8, 2026. https://www.gene.com/media/press-releases/15106/2026-03-08/genentech-provides-update-on-phase-iii-p
2. April 30, 2026 meeting of the Oncologic Drugs Advisory Committee (ODAC). FDA. Accessed May 8, 2026. https://www.youtube.com/live/taCx7enN7hk